Global Blood Therapeutics, Inc.
GBT was delisted on the 4th of October, 2022.
206 hedge funds and large institutions have $1.89B invested in Global Blood Therapeutics, Inc. in 2021 Q4 according to their latest regulatory filings, with 52 funds opening new positions, 61 increasing their positions, 64 reducing their positions, and 30 closing their positions.
133% more funds holding in top 10
Funds holding in top 10: 3 → 7 (+4)
73% more first-time investments, than exits
New positions opened: 52 | Existing positions closed: 30
48% more call options, than puts
Call options by funds: $13.1M | Put options by funds: $8.9M
24% more capital invested
Capital invested by funds: $1.52B → $1.89B (+$367M)
10% more funds holding
Funds holding: 187 → 206 (+19)
5% less repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 64
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$51.1M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$39.5M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$26.7M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
+$23.2M |
| 5 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
+$15.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$66M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$33.4M |
| 3 |
PA
Perceptive Advisors
New York
|
-$29.7M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
-$24.5M |
| 5 |
CC
Casdin Capital
New York
|
-$18.6M |
GBT Hedge Fund Activity: Q4 2021 in Review
206 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Global Blood Therapeutics, Inc. (GBT) for Q4 2021, worth a combined $1.89B — up 24% from $1.52B a quarter earlier.
Buyers outnumbered sellers: 52 funds opened new GBT positions and 30 closed out — a net gain of 22 holders — while 61 added to existing stakes and 64 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $51.1M. The largest seller was Point72 Asset Management, cutting an estimated $66M.
- 206 institutional investors held Global Blood Therapeutics, Inc. (GBT) as of Q4 2021, up from 187 in Q3 2021.
- Funds reported $1.89B of Global Blood Therapeutics, Inc. stock for Q4 2021, up 24% quarter-over-quarter.
- 52 funds opened new Global Blood Therapeutics, Inc. positions in Q4 2021 and 30 closed out, a net change of +22 holders.
- The largest Global Blood Therapeutics, Inc. buyer in Q4 2021 was Citadel Advisors, an estimated $51.1M added.
- The largest Global Blood Therapeutics, Inc. seller in Q4 2021 was Point72 Asset Management, an estimated $66M sold.
Based on aggregated 13F filings for Q4 2021.